Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

ADMA Insider Trading

Adma Biologics Inc. | Biological Products, (No Diagnostic Substances)

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Adma Biologics Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2020-09-10 15:00 2020-09-08 Grossman Adam S Director, Officer - President and CEO BUY $2.24 4,000 $8,960 176,098 +2.3%
2020-08-25 15:00 2020-08-21 Grossman Jerrold B Director BUY $2.56 5,300 $13,586 155,864 +3.5%
2020-08-14 15:00 2020-08-13 DEMSKI MARTHA J Director BUY $2.88 2,000 $5,760 2,000 +100.0%
2020-08-13 15:01 2020-08-12 Grossman Jerrold B Director BUY $2.89 10,200 $29,499 150,564 +7.3%
2020-08-12 15:02 2020-08-10 Grossman Adam S Director, Officer - President and CEO BUY $3.04 6,000 $18,260 172,098 +3.6%
2020-08-12 15:01 2020-08-10 Mond James Officer - EVP, CSO and CMO BUY $2.88 7,000 $20,150 69,174 +11.3%
2020-08-12 15:02 2020-08-11 LENZ BRIAN Officer - EVP, CFO BUY $2.97 4,000 $11,860 76,142 +5.5%
2020-03-23 15:30 2020-03-19 PERCEPTIVE ADVISORS LLC 10% owner BUY $2.10 500,000 $1,050,000 16,584,802 +3.1%
2020-02-11 18:18 2020-02-11 Guiheen Lawrence P. Director BUY $3.50 20,000 $70,000 70,000 +40.0%
2020-02-11 18:16 2020-02-11 Mond James Officer - CSO and CMO BUY $3.50 4,285 $14,998 22,174 +24.0%
2020-02-11 18:15 2020-02-11 Grossman Jerrold B Director BUY $3.50 45,714 $159,999 22,857 +100.0%
2020-02-11 18:11 2020-02-11 Grossman Adam S Director, Officer - President and CEO BUY $3.50 85,714 $299,999 878,444 +10.8%
2020-02-11 18:13 2020-02-11 LENZ BRIAN Officer - EVP, CFO BUY $3.50 7,142 $24,997 32,142 +28.6%
2020-02-11 16:02 2020-02-11 PERCEPTIVE ADVISORS LLC 10% owner BUY $3.50 4,563,700 $15,972,950 16,084,802 +39.6%
2019-06-07 23:25 2019-06-06 Biotest Divestiture Trust 10% owner SELL $3.75 5,813,954 $21,802,328 4,295,580 -57.5%
2019-05-23 15:32 2019-05-21 PERCEPTIVE ADVISORS LLC 10% owner BUY $4.00 4,000,000 $16,000,000 11,521,102 +53.2%
2019-05-21 14:14 2019-05-17 Grossman Jerrold B Director BUY $4.00 12,000 $48,000 110,007 +12.2%
2019-05-21 14:13 2019-05-17 Guiheen Lawrence P. Director BUY $4.00 25,000 $100,000 50,000 +100.0%
2019-05-21 14:12 2019-05-17 Mond James Officer - EVP, CSO and CMO BUY $4.00 4,500 $18,000 17,889 +33.6%
2019-05-21 14:11 2019-05-17 Grossman Adam S Director, Officer - President and CEO BUY $4.00 30,000 $120,000 821,301 +3.8%
2019-05-21 14:12 2019-05-17 LENZ BRIAN Officer - EVP, CFO BUY $4.00 5,000 $20,000 25,000 +25.0%
2018-08-09 23:33 2018-05-14 Biotest Divestiture Trust 10% owner SELL $0.00 8,591,160 $0 0 -100.0%
2018-06-11 14:10 2018-06-08 Grossman Jerrold B Director BUY $4.78 52,302 $250,004 31,381 +100.0%
2018-06-11 14:09 2018-06-08 Grossman Adam S Director, Officer - President and CEO BUY $4.78 73,222 $350,001 796,301 +10.1%
2018-06-11 14:09 2018-06-08 Guiheen Lawrence P. Director BUY $4.78 20,000 $95,600 25,000 +400.0%
2018-06-11 14:08 2018-06-08 RICHMAN ERIC I Director BUY $4.78 5,230 $24,999 36,530 +16.7%
2018-06-11 14:08 2018-06-08 LENZ BRIAN Officer - VP, CFO BUY $4.78 5,000 $23,900 20,000 +33.3%
2018-05-17 00:00 2018-05-14 Biotest AG 10% owner SELL $0.00 8,591,160 $0 0 -100.0%
2017-11-13 21:54 2017-11-09 Biotest AG Director, 10% owner BUY $2.15 5,813,954 $12,500,001 10,109,534 +135.3%
2017-11-13 21:46 2017-11-09 Grossman Adam S Director, Officer - President and CEO BUY $2.15 485,000 $1,042,750 744,000 +187.3%
2017-11-13 21:45 2017-11-09 Mond James Officer - EVP, CSO and CMO BUY $2.15 10,000 $21,500 13,389 +295.1%
2017-11-13 21:51 2017-11-09 RICHMAN ERIC I Director BUY $2.15 25,000 $53,750 31,300 +396.8%
2017-11-13 21:49 2017-11-09 LENZ BRIAN Officer - VP, CFO BUY $2.15 6,500 $13,975 15,000 +76.5%
2016-05-06 02:27 2016-05-03 Mond James Officer - CSO/CMO BUY $6.50 770 $5,005 3,389 +29.4%
2016-05-06 02:26 2016-05-03 Grossman Adam S Director, Officer - President & CEO BUY $6.50 200,000 $1,300,000 843,668 +31.1%
2016-05-06 02:25 2016-05-03 Grossman Jerrold B Director BUY $6.50 45,769 $297,499 106,327 +75.6%
2016-05-06 02:26 2016-05-03 LENZ BRIAN Officer - Chief Financial Officer BUY $6.50 2,500 $16,250 8,500 +41.7%
2015-12-22 16:01 2015-12-18 Grossman Jerrold B Director BUY $8.48 4,000 $33,918 60,558 +7.1%
2015-12-22 16:00 2015-12-18 Grossman Adam S Director, Officer - President & CEO BUY $8.47 6,400 $54,224 643,668 +1.0%
2015-12-09 16:01 2015-12-07 Grossman Jerrold B Director BUY $9.01 500 $4,503 56,558 +0.9%
2015-12-09 16:01 2015-12-07 Grossman Adam S Director, Officer - President & CEO BUY $9.00 500 $4,501 637,268 +0.1%
2015-12-05 00:05 2015-12-02 Grossman Jerrold B Director BUY $9.16 6,000 $54,961 56,058 +12.0%
2015-12-04 14:06 2015-12-02 Grossman Adam S Director, Officer - President & CEO BUY $9.15 2,250 $20,584 636,768 +0.4%
2015-12-03 15:59 2015-12-01 Grossman Adam S Director, Officer - President & CEO BUY $9.17 1,800 $16,513 634,518 +0.3%
2015-12-03 15:56 2015-12-02 LENZ BRIAN Officer - Chief Financial Officer BUY $9.15 1,000 $9,151 6,000 +20.0%
2015-12-01 00:31 2015-11-25 Grossman Adam S Director, Officer - President & CEO BUY $9.18 1,800 $16,529 632,718 +0.3%
2015-11-24 00:05 2015-11-19 Grossman Adam S Director, Officer - President & CEO BUY $9.21 3,861 $35,572 630,918 +0.6%
2015-03-23 23:19 2015-03-19 Grossman Adam S Director, Officer - President & CEO BUY $8.50 2,000 $16,997 627,057 +0.3%
2015-03-23 23:20 2015-03-19 LENZ BRIAN Officer - Chief Financial Officer BUY $8.95 750 $6,714 5,000 +17.6%
2015-03-19 04:59 2015-03-16 Guiheen Lawrence P. Director BUY $7.96 1,000 $7,959 6,000 +20.0%
SHOW ENTRIES

How to Interpret $ADMA Trades

Not every insider transaction in Adma Biologics Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $ADMA shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for ADMA

Insider activity data for Adma Biologics Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $ADMA, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.